FosterNC, BeckRW, MillerKM, et al.: State of type 1 diabetes management and outcomes from the Type 1 Diabetes Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21:66–72; doi: 10.1089/dia.2018.0384
2.
WadwaRP, LaffelLM, ShahVN, GargSK: Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes. Diabetes Technol Ther, 2018; 20:395–402.
3.
GargSK, AkturkHK: A new era in continuous glucose monitoring: Food and Drug Administration creates a new category of factory-calibrated nonadjunctive, interoperable Class II medical devices. Diabetes Technol Ther, 2018; 20:391–394.
4.
ShahVN, LaffelLM, WadwaRP, GargSK: Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther, 2018; 20:428–433.
5.
AkturkHK, Snell-BergeonJK, RewersA, et al.: Improved postprandial glucose with inhaled Technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther, 2018; 20:639–647.
6.
BeckRW, BergenstalRM, RiddlesworthTD, KollmanC: The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. Diabetes Technol Ther, 2019; 21:1–5.
7.
RodbardD: State of type 1 diabetes care in the US in 2016–2018 from T1D Exchange registry data. Diabetes Technol Ther, 2019; 21:62–65. doi:10.1089/dia.2019.0008.
8.
GargSK: Expanding treatment options for improving health outcomes in type 1 diabetes. Diabetes Technol Ther, 2017; 19:549–551.
9.
HenryRR, StrangeP, ZhouR, et al.: Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Technol Ther, 2018; 20:715–724.
GargSK, PetersAL, BuseJB, DanneT. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH Protocol. Diabetes Technol Ther, 2018; 20:571–575.
12.
Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), January 17, 2019. https://www.fda.gov/AdvisoryCommittees/Calendar/ucm627271.htm, accessed January3, 2019.
